Screening cancer patients for distress - why it is important and current issues

Screening cancer patients for distress - why it is important and current issues

VJOncology

2 years
936 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Alex Mitchell, MBBS, BMedSci, MSc, MD, MCPsyc, of the University of Leicester, UK, gives an overview of his talk on screening cancer patients for distress at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK. Prof. Mitchell starts by explaining that many centers have now introduced screening although the different measures that are used are quite unwieldy. Increasingly we are moving to user-friendly tools, which are simple and easy to interpret for patients. However, even with those tools, the question is how accurate they are and if they are being implemented around the world. Prof. Mitchell explains that without tools, we know that clinicians struggle to detect distress, depression, and anxiety; detecting only less than half of those key mental health areas. With tools, things have improved but unfortunately not as much as we expect. There are in fact many barriers to the implementation of the stress screening and one classic barrier is that clinicians feel they do not have enough time. Sometimes, patients may feel the tools interfere with their consultation, and they would rather be speaking to their clinician one to one than filling out a form. He explains that overall, it is known from the evidence that screening for distress does improve distress management, however, only by a modest degree of about 10-20% overall.
Up Next Autoplay
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
19 Views
SeattleCCA 4 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
11 Views
Cancer-News 4 days
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
7 Views
MD Anderson 4 days
KY1044 Targets ICOS @kymabltd @rcasainson
KY1044 Targets ICOS @kymabltd @rcasainson
Category: Other
3 Views
Cancer-News 4 days
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
Category: Other
6 Views
Cancer-News 4 days
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
24 Views
MD Anderson 4 days
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
Category: Other
12 Views
Cancer-News 4 days
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Category: News
8 Views
OSUCCC 4 days
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Category: Multiple Myeloma
12 Views
Cancer-News 5 days
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Category: News
17 Views
OSUCCC 5 days